Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Oct 1;200(7):802-804.
doi: 10.1164/rccm.201905-1092ED.

Predictive Biomarkers of Response to Src Inhibitors in Lung Cancer. Getting to YES1

Howard Y Li  1   2 , Laurie L Carr  3
Affiliations
Editorial

Predictive Biomarkers of Response to Src Inhibitors in Lung Cancer. Getting to YES1

Howard Y Li et al. Am J Respir Crit Care Med. .
No abstract available

PubMed Disclaimer

Comment on

  • YES1 Drives Lung Cancer Growth and Progression and Predicts Sensitivity to Dasatinib.
    Garmendia I, Pajares MJ, Hermida-Prado F, Ajona D, Bértolo C, Sainz C, Lavín A, Remírez AB, Valencia K, Moreno H, Ferrer I, Behrens C, Cuadrado M, Paz-Ares L, Bustelo XR, Gil-Bazo I, Alameda D, Lecanda F, Calvo A, Felip E, Sánchez-Céspedes M, Wistuba II, Granda-Diaz R, Rodrigo JP, García-Pedrero JM, Pio R, Montuenga LM, Agorreta J. Garmendia I, et al. Am J Respir Crit Care Med. 2019 Oct 1;200(7):888-899. doi: 10.1164/rccm.201807-1292OC. Am J Respir Crit Care Med. 2019. PMID: 31166114

References

    1. Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, et al. SEER cancer statistics review, 1975-2016. Bethesda, MD: National Cancer Institute; 2019 [accessed 2019 May 25]. Available from: https://seer.cancer.gov/csr/1975_2016/
    1. Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev. 2003;22:337–358. - PubMed
    1. Mazurenko NN, Kogan EA, Zborovskaya IB, Kisseljov FL. Expression of pp60c-src in human small cell and non-small cell lung carcinomas. Eur J Cancer. 1992;28:372–377. - PubMed
    1. Laurie SA, Goss GD, Shepherd FA, Reaume MN, Nicholas G, Philip L, et al. A phase II trial of saracatinib, an inhibitor of src kinases, in previously-treated advanced non-small-cell lung cancer: the princess margaret hospital phase II consortium. Clin Lung Cancer. 2014;15:52–57. - PubMed
    1. Johnson FM, Bekele BN, Feng L, Wistuba I, Tang XM, Tran HT, et al. Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2010;28:4609–4615. - PMC - PubMed